“The microbiome represents a novel and exciting therapeutic target, with a critical function in the maintenance of immune homeostasis, and a dysfunctional microbiome is linked to a diverse range of disease states. Moreover, accumulating data suggests that individual-to-individual microbiome heterogeneity can impact the efficacy of small-molecules and biologics. Additionally, Phase III clinical success has been reported with an oral microbiome-based therapy targeting C. difficile infection, further supporting continued microbiome R&D investment. As the role for the microbiome in health and disease is increasingly appreciated, understood, and commercialized, it’s critical to consider the microbiome in your preclinical research.
This webinar will discuss approaches and considerations that are applicable to both disease phenotype targeting and biologic/small molecule efficacy targeting strategies in preclinical microbiome research. Discussed approaches will include fecal microbial transplant, “bugs as drugs,” antibiotic pre-treatment paradigms, and how germ-free mice can be used to support a microbiome research program. We will provide examples of experimental systems designed to address proof-of-concept, mechanism of action, and efficacy questions. The webinar will conclude with a discussion of several microbiome-focused study designs and data sets.”